CBD Oil for Sleep and Fibromyalgia: How CBD Addresses Central Sensitization, Alpha-Delta Sleep Anomaly, Widespread Pain Nocturnal Arousal, Fibro Fog, and the Fibromyalgia-Sleep Bidirectional Relationship

By PureCraft Editorial Team | PureCraft CBD | Updated October 2026

Fibromyalgia is one of the conditions in which the relationship between pain and sleep is most deeply and inextricably bidirectional: fibromyalgia causes sleep disruption through central sensitization-driven nocturnal pain amplification and the alpha-delta sleep anomaly (intrusive alpha-frequency EEG waves that interrupt N3 slow-wave sleep, destroying its restorative quality); and disrupted sleep worsens fibromyalgia pain through the well-documented bidirectional cycle where sleep deprivation lowers the central pain threshold, amplifying fibromyalgia's already-sensitized pain processing. The fibromyalgia-sleep relationship is distinct from simply having chronic pain that interferes with sleep — fibromyalgia's mechanism of sleep disruption is neurological rather than primarily nociceptive: it is the brain's pain-processing system itself that generates disordered sleep, through a central sensitization state in which the central nervous system amplifies pain signals, reduces the activation threshold for nociception, and produces the allodynia and hyperalgesia that make nocturnal pressure from mattresses, sheets, and the patient's own body weight into significant pain stimuli.

The population is substantial: fibromyalgia affects an estimated 4 million adults in the United States (approximately 2% of the adult population), with women comprising 75–90% of diagnosed patients. Sleep disturbance is present in 96–99% of fibromyalgia patients — making it the highest co-prevalence of any single symptom — and non-restorative sleep is one of the four primary diagnostic criteria (alongside widespread pain, fatigue, and cognitive symptoms). CBD oil's mechanisms engage fibromyalgia's sleep biology at multiple points: TRPV1 desensitization (peripheral and spinal sensitization contributions to fibromyalgia allodynia), FAAH inhibition with anandamide elevation (endocannabinoid system deficiency is a proposed mechanism in fibromyalgia — the clinical endocannabinoid deficiency hypothesis), CB2 anti-inflammatory (neuroinflammatory component of central sensitization), 5-HT1A partial agonism (fibromyalgia anxiety and HPA hyperactivation — co-occurring anxiety disorders in 30–40% of fibromyalgia patients), adenosine A1 N3 amplification (directly addressing the alpha-delta anomaly's disruption of N3 depth), and HPA normalization (the persistent cortisol dysregulation of fibromyalgia). The honest context: fibromyalgia clinical trials with CBD are limited as of October 2026; the mechanistic basis is compelling but the clinical evidence is preliminary, and fibromyalgia represents one of the conditions where CBD's mechanisms are most theoretically coherent with the pathophysiology — but where the evidence-to-mechanism ratio most warrants the realistic framing that mechanism does not guarantee clinical effect size.

How Fibromyalgia Disrupts Sleep: Five Core Mechanisms

1. The Alpha-Delta Sleep Anomaly: The Neurological Fingerprint of Fibromyalgia Sleep Disruption

The alpha-delta sleep anomaly is the most fibromyalgia-specific sleep EEG finding in medicine — and it is the sleep mechanism that most clearly demonstrates why fibromyalgia is a neurological rather than merely musculoskeletal condition. In normal N3 slow-wave sleep (delta sleep), the EEG is dominated by high-amplitude, low-frequency delta waves (0.5–4 Hz) — the signature of the deep, restorative sleep phase during which growth hormone secretion, immune consolidation, memory consolidation, and glymphatic waste clearance occur. In fibromyalgia, sleep laboratory EEG consistently shows intrusive alpha waves (8–12 Hz, the alert-resting wakefulness frequency) superimposed on the delta background during N3 — producing the characteristic "alpha-delta" or "alpha-NREM" EEG pattern. This pattern was first described by Harvey Moldofsky in the early 1970s and has been replicated across decades of fibromyalgia sleep research as a condition-defining finding. The functional consequence: the brain is simultaneously attempting slow-wave sleep (delta oscillations) while the thalamus is generating wake-state alpha rhythms that prevent the sustained delta needed for restorative N3. Sleep time is logged as N3 (by standard polysomnographic scoring criteria) but its biological quality is severely compromised — patients spend time in the "deep sleep" stage without receiving its restorative benefit. This explains the core paradox of fibromyalgia sleep: patients are exhausted, they sleep for what appears to be adequate duration, but they wake feeling completely unrestored — the "I slept 9 hours and feel like I haven't slept at all" that characterizes fibromyalgia sleep experience. The thalamic mechanism driving the alpha-delta anomaly is directly connected to fibromyalgia's central sensitization state: the same thalamic hyperexcitability and impaired descending pain inhibition that amplifies ascending nociceptive signals during waking is maintaining thalamic arousal signaling during sleep — the brain cannot fully disengage from the pain-vigilance mode that central sensitization requires during waking, producing the alpha intrusion into N3. This same mechanism was described in the ME/CFS post (P11-184) — where it was called the alpha-delta anomaly in the context of thalamic neuroinflammation — but in fibromyalgia the mechanism is thalamic central sensitization-driven hyperexcitability rather than the neuroinflammatory glial activation of ME/CFS. The two conditions share the sleep EEG phenotype but through somewhat different thalamic pathophysiology.

2. Central Sensitization and Allodynia: Nocturnal Pain Amplification

Central sensitization is the defining pathophysiological mechanism of fibromyalgia — and it is the mechanism that makes fibromyalgia sleep disruption fundamentally different from pain-related sleep disruption in other chronic pain conditions. Central sensitization refers to a state of amplified neural signaling in the central nervous system in which the pain-processing pathways have increased responsiveness: the threshold for pain activation is lowered (hyperalgesia — pain is experienced from stimuli that would normally produce mild pain), non-painful stimuli generate pain (allodynia — light touch, pressure, temperature change, fabric contact), and the spatial and temporal summation of pain is exaggerated (wider area of pain from focal stimulus; "wind-up" where repeated stimuli produce exponentially escalating pain). In fibromyalgia, this central sensitization is widespread and not localized to a site of injury or inflammation — the pain amplification is global, involving the entire body, because it is a CNS regulatory disorder of pain processing rather than a tissue-level inflammation-driven disorder. The nocturnal consequences of fibromyalgia allodynia are unique in the chronic pain landscape: lying down on a mattress produces significant pain from the pressure of body weight on sensitized skin and soft tissue pressure receptors; the weight of bed sheets on extremities produces allodynic pain from fabric pressure; changing position during normal sleep micro-movements generates pain that causes micro-arousals and full awakenings; and the normal decrease in descending pain inhibition during sleep (the brainstem descending inhibitory pathways — noradrenergic and serotonergic — partially reduce their activity during sleep relative to active waking) disinhibits the already-central-sensitized ascending pain system, producing nocturnal pain amplification that is measurably worse than daytime pain for many fibromyalgia patients. The nocturnal allodynia of fibromyalgia is therefore not just chronic pain keeping the patient awake — it is chronic pain that is specifically amplified during sleep through the normal sleep-state reduction of descending inhibition, creating a sleep-specific pain mechanism unique to central sensitization conditions.

3. HPA Axis Dysregulation: The Fibromyalgia Cortisol Pattern

Fibromyalgia is associated with a characteristic HPA axis dysregulation that is distinct from the HPA hyperactivation of cancer anxiety or the HPA hypo-responsiveness of ME/CFS: fibromyalgia patients show an altered cortisol rhythm characterized by blunted morning cortisol rise (the cortisol awakening response — CAR — is attenuated in fibromyalgia; this reduced morning cortisol peak correlates with the morning fatigue and stiffness severity), elevated basal evening/nighttime cortisol relative to normal (partial disruption of the cortisol nadir), and a hyperactivated HPA response to stress (CRF hypersecretion in the paraventricular nucleus → exaggerated ACTH and cortisol response to psychosocial stressors). The elevated evening and nighttime cortisol directly interferes with N3 sleep onset (cortisol suppresses delta oscillation depth) and maintains HPA-driven sympathetic arousal during the night that should be predominantly parasympathetic. The morning CAR blunting produces the waking pattern of fibromyalgia: patients describe being at their worst upon awakening — stiff, painful, cognitively fogged, exhausted despite having been in bed — because the morning cortisol rise that normally mobilizes glucose, suppresses inflammation, reduces morning pain sensitivity (cortisol's physiological anti-inflammatory role), and promotes cognitive alertness is blunted. The HPA dysregulation in fibromyalgia is partly driven by the chronic stress of living with unrelenting pain (the pain itself driving HPA activation), partly by the sleep disruption that the alpha-delta anomaly produces (sleep deprivation impairs normal HPA rhythm), and partly by the neurological dysregulation of CRF pathways that characterizes fibromyalgia's central sensitization — the same thalamic and brainstem circuitry that produces central pain amplification also dysregulates stress-responsive HPA circuits.

4. Fibromyalgia Anxiety, Hypervigilance, and the Pain-Catastrophizing Arousal Loop

Anxiety disorders co-occur in 30–40% of fibromyalgia patients, and even in patients without diagnosable anxiety disorders, fibromyalgia produces a characteristic pattern of pain catastrophizing — a cognitive-emotional amplification of pain through rumination, magnification, and helplessness — that directly worsens both the pain experience and sleep. Pain catastrophizing maintains hyperarousal through the same amygdala-HPA-sympathetic mechanism as anxiety disorders: catastrophic pre-sleep thoughts about pain ("the pain will be unbearable tonight," "I'll never sleep through this pain," "this pain will be worse tomorrow") activate the amygdala's threat-detection circuit, drive HPA cortisol elevation, and maintain the sympathetic nervous system in the activated state that suppresses parasympathetic sleep-onset physiology. The hypervigilance of fibromyalgia — the heightened sensory awareness to bodily sensations that is both a symptom and a maintaining mechanism — is particularly sleep-disruptive: patients who have learned to monitor their pain (understandably, given its severity and variability) cannot easily disengage the vigilance network during sleep-onset. The insula (interoceptive awareness), anterior cingulate cortex (pain salience), and amygdala (threat detection) remain in a partially activated state, generating the pre-sleep rumination about pain that prevents sleep onset. The fibromyalgia "flare" anxiety — the anticipatory dread of days or weeks of increased pain intensity that characterize fibromyalgia's waxing-and-waning course — produces episodic acute anxiety on top of the chronic pain catastrophizing background, worsening sleep during flares and creating pre-flare sleep anxiety that can worsen the flare itself through the bidirectional pain-sleep amplification cycle.

5. The Bidirectional Fibromyalgia–Sleep Cycle: Sleep Deprivation as a Fibromyalgia Amplifier

The bidirectional relationship between fibromyalgia and sleep is among the most well-documented in chronic pain medicine, and the fibromyalgia-sleep bidirectional cycle represents a particularly vicious feedback loop: fibromyalgia disrupts sleep through the alpha-delta anomaly and nocturnal allodynia; disrupted sleep lowers the central pain threshold through multiple mechanisms (reduction in descending serotonergic/noradrenergic inhibition from brainstem sleep deprivation; reduction in endogenous opioid activity; increase in substance P, a key central sensitization neuropeptide, following sleep deprivation; and increase in systemic inflammatory cytokines from sleep deprivation that are themselves pronociceptive); the lowered pain threshold from sleep deprivation amplifies fibromyalgia's already central-sensitized pain processing; the amplified pain produces worse sleep disruption; and the cycle compounds. Moldofsky's original fibromyalgia research demonstrated this bidirectionally experimentally: healthy volunteers subjected to alpha-delta sleep deprivation (using acoustic tones to interrupt N3 during sleep) developed fibromyalgia-like widespread musculoskeletal pain and tender points, confirming that the alpha-delta sleep disruption itself is sufficient to generate fibromyalgia-like pain in people without the underlying central sensitization — and conversely, that restoring N3 sleep quality is a genuine treatment target in fibromyalgia. The clinical implication: treating fibromyalgia sleep disruption is not just addressing a symptom — it is intervening in the primary amplification cycle that maintains fibromyalgia pain severity. Sleep improvement in fibromyalgia is itself pain treatment.

Fibromyalgia Sleep Disruption: Mechanism Summary

CBD Oil's Mechanisms for Fibromyalgia Sleep Disruption

The Clinical Endocannabinoid Deficiency Hypothesis: CBD's Most Fibromyalgia-Specific Mechanism

The clinical endocannabinoid deficiency (CED) hypothesis — advanced by Ethan Russo and colleagues — proposes that fibromyalgia, migraine, and irritable bowel syndrome (IBS) represent a cluster of conditions sharing a common underlying pathology: insufficient endocannabinoid tone in the central nervous system. The hypothesis rests on several observations: fibromyalgia patients show reduced anandamide levels in cerebrospinal fluid; cannabinoid receptor density and sensitivity appear altered in fibromyalgia; the pattern of central sensitization in fibromyalgia overlaps with the regulatory domains of the endocannabinoid system (ECS) in pain processing, sleep-wake cycling, and HPA regulation; and multiple fibromyalgia symptoms — widespread pain, sleep disruption, cognitive fog, anxiety, GI symptoms — map onto ECS regulatory functions. The clinical endocannabinoid deficiency framework makes CBD's FAAH inhibition particularly relevant to fibromyalgia: by inhibiting the FAAH enzyme that degrades anandamide, CBD elevates anandamide levels — potentially restoring some of the endocannabinoid tone that the CED hypothesis identifies as deficient. The anandamide elevation from CBD FAAH inhibition addresses multiple fibromyalgia mechanisms simultaneously: anandamide's CB1 agonism at thalamic relay neurons may reduce the hyperexcitability driving alpha-delta anomaly (CB1 is expressed in thalamic relay nuclei and modulates their firing rate); anandamide's CB1 activation at spinal dorsal horn inhibitory synapses reduces the central sensitization wind-up mechanism; anandamide's endogenous TRPV1 agonism (anandamide is a TRPV1 agonist at higher concentrations, inducing desensitization through the same calcium-dependent internalization mechanism as CBD's direct TRPV1 agonism); and anandamide's CB2 activity provides an endogenous anti-inflammatory signal in fibromyalgia's central nervous system glial compartment. The CED hypothesis is not proven clinical fact — it is a well-constructed theoretical framework with preliminary supporting evidence — but it represents the most fibromyalgia-specific mechanistic basis for CBD's potential benefit in this condition in this series.

Adenosine A1 Activation: The Alpha-Delta Anomaly Target

Adenosine is the brain's primary sleep-pressure signal — the accumulation of extracellular adenosine during waking hours drives the homeostatic sleep drive (Process S) that builds pressure to sleep, and adenosine's A1 receptor activation is one of the primary mechanisms through which deep N3 slow-wave sleep is initiated and maintained. CBD's FAAH inhibition elevates extracellular adenosine through the same mechanism by which it elevates anandamide: FAAH also metabolizes AMP (adenosine monophosphate) to adenosine and then further processes adenosine products; more relevantly, CBD's inhibition of the adenosine transporter ENT1 (equilibrative nucleoside transporter 1) reduces reuptake of extracellular adenosine, maintaining higher extracellular adenosine concentrations. The elevated adenosine from CBD's mechanisms activates A1 receptors on thalamic relay neurons — the same thalamic neurons whose hyperexcitability generates the alpha-delta anomaly's intrusive alpha oscillations. A1 receptor activation in thalamic relay neurons produces membrane hyperpolarization through Gi-coupled KATP channel opening, reducing thalamic relay neuron firing rate and promoting the burst-firing mode that characterizes delta oscillation generation rather than the tonic high-frequency firing mode that generates alpha rhythms. This is the most mechanistically direct CBD intervention on the alpha-delta anomaly: adenosine A1 activation suppresses thalamic relay neuron alpha-frequency firing, potentially reducing alpha wave intrusion into N3 and allowing deeper, more sustained delta oscillations — translating into more restorative N3 sleep quality. The clinical prediction: fibromyalgia patients using CBD oil may experience improvement in subjective sleep quality (feeling more rested upon waking) before improvements in sleep duration or sleep-onset latency, because the adenosine mechanism addresses the quality dimension (N3 restoration) rather than the quantity dimension (total sleep time or sleep-onset speed) of fibromyalgia sleep disruption. This mechanism is shared with ME/CFS (P11-184) but applied to fibromyalgia's central sensitization-driven alpha-delta anomaly rather than ME/CFS's neuroinflammation-driven thalamic pathology.

TRPV1 Desensitization and Endocannabinoid Analgesia: Addressing Nocturnal Allodynia

Fibromyalgia allodynia — pain from normally non-painful stimuli including light touch and pressure — has both peripheral and central components, and TRPV1 desensitization and endocannabinoid analgesia address each. At the peripheral level: fibromyalgia patients show upregulated TRPV1 expression in skin C-fibers relative to healthy controls, with increased neuropeptide (substance P, CGRP) release from sensitized afferents; CBD's TRPV1 desensitization reduces C-fiber sensitization, raising the mechanical and thermal allodynic threshold in skin and subcutaneous sensory endings. The practical outcome: reduced pain from mattress pressure, sheet weight, and position-change-driven mechanical stimuli that generate nocturnal arousal through allodynic activation of sensitized peripheral C-fibers. At the spinal level: the wind-up phenomenon — where repeated C-fiber stimulation from ongoing contact with bedding during sleep produces exponentially increasing pain — is driven by NMDA receptor activation in spinal dorsal horn neurons and substance P/NK1 receptor sensitization; CBD's anandamide elevation at CB1 receptors on spinal dorsal horn interneurons reduces the excitatory synaptic drive maintaining wind-up, reducing the temporal summation that makes repeated mild stimuli during repositioning generate severe pain. CBD's spinal analgesia through endocannabinoid tone restoration addresses the central mechanism of fibromyalgia pain amplification rather than just the peripheral afferent contribution — making it mechanistically distinct from analgesics that act primarily peripherally (NSAIDs, which are largely ineffective in fibromyalgia for this same reason: fibromyalgia pain is not primarily peripheral inflammation-driven, and addressing peripheral inflammation doesn't substantially reduce central sensitization).

Honest Evidence Assessment: CBD Oil and Fibromyalgia

Fibromyalgia Condition-Specific Dosing Profiles

PureCraft Products for Fibromyalgia Sleep Disruption

Foundation: Sublingual Oil for Flexible Titration in a Sensitive Population

Nano CBD Broad Spectrum Oil — Fibromyalgia patients are characteristically a highly medication-sensitive population — the same central sensitization that amplifies pain also amplifies responses to new pharmacological agents, making incremental titration with a precisely dose-adjustable format essential. The sublingual nanoemulsion oil's 0.5 mL / 1 mL incremental dosing allows the fine-grained titration that fibromyalgia patients need: starting at a half-dropper (approximately 10 mg), holding for 3 weeks to assess fibromyalgia-specific sensitivity, and advancing in half-dropper increments rather than the full-dropper increments that non-sensitive populations tolerate. The nanoemulsion's consistent 50–80% bioavailability provides reliable plasma levels without the absorption variability that makes oral CBD in fibromyalgia unpredictable — absorption variability with standard CBD oil would make distinguishing medication sensitivity responses from dose-level changes difficult in titration. Sublingual administration (hold 60–90 seconds under tongue before swallowing) provides faster onset than softgels — relevant for fibromyalgia patients taking CBD close to bedtime when allodynic pain arousal is already beginning. Beta-caryophyllene, linalool, and myrcene terpenes in broad spectrum oil provide direct CB2 and GABAergic contributions to central sensitization modulation. Take with a small fat-containing food (2 hours after last fibromyalgia medication if on CYP2D6-metabolized agents), 45 minutes before intended sleep.

Overnight Allodynia and Pain Coverage

Nano CBD Water-Soluble Broad Spectrum Softgels — Fibromyalgia allodynia and central sensitization pain are persistent throughout the night — not episodic or position-change-specific — requiring sustained nocturnal CBD coverage that the sublingual oil's 4–6 hour peak duration may not fully provide through a 7–8 hour sleep window. A bedtime softgel's water-soluble nano-emulsion in a softgel matrix provides extended-release CBD that bridges the late-night hours (3–7 AM) when fibromyalgia pain intensity often increases (the reduced descending inhibition of late-night sleep stages, the cortisol nadir reducing anti-inflammatory cortisol activity, and the light sleep stages of the latter sleep cycle providing less masking of pain signals). Adding the softgel after at least 4 weeks on the oil at a stable dose allows the incremental fibromyalgia-appropriate titration approach; the total daily dose (oil + softgel combined) guides the physician disclosure conversation for CYP-interacting medication patients. The overnight CB2 anti-inflammatory coverage from the softgel addresses the neuroinflammatory component of central sensitization — the microglial and astrocyte activation in the spinal dorsal horn and brainstem that maintains central sensitization is a persistent state requiring sustained anti-inflammatory coverage rather than just evening peak coverage, making the extended overnight softgel profile more aligned with central sensitization's 24-hour inflammatory state than the oil alone.

Daytime Anxiety and Flare Pre-Sleep Arousal

Nano CBD Infused Vegan Broad Spectrum Gummies — Fibromyalgia's anxiety component — the pain catastrophizing, hypervigilance, and flare anticipatory anxiety that builds through the day and arrives at bedtime as pre-sleep arousal — benefits from a mid-afternoon 5–10 mg gummy (around 3–4 PM) that positions CBD's 5-HT1A anxiolytic activity at the peak anxiety-building period, reducing the amygdala hyperreactivity that would otherwise arrive at bedtime as entrenched pre-sleep rumination. The mid-afternoon timing is distinct from the bedtime dosing of the oil: it engages the HPA normalization mechanism during the HPA-activation buildup period (cortisol is often dysregulated in fibromyalgia's late afternoon pattern), rather than at bedtime when the HPA hyperactivation is already fully established and harder to attenuate. The broad spectrum (THC-free) gummies are appropriate for fibromyalgia patients who need consistent daytime function and cannot tolerate any psychoactive effects that might affect work, driving, or activity. For fibromyalgia flare weeks — when pain is worst, sleep is most disrupted, and anxiety is highest — maintaining the afternoon gummy consistently through the flare period rather than abandoning CBD when dosing feels difficult provides the most support through the worst phase of the fibromyalgia cycle.

Deep Sleep Support and Muscle Discomfort

Nano CBD Infused Muscle and Joint Cream — Topical CBD application to fibromyalgia tender points and areas of highest allodynic sensitivity before sleep provides a localized TRPV1 desensitization mechanism at the peripheral C-fiber level — complementary to the systemic central mechanism of oral CBD. Fibromyalgia patients often identify specific regions of worst nocturnal allodynia (commonly the neck/trapezius tender points, the lateral epicondyle area, the knees, and the costochondral junctions), and applying topical CBD cream 30–45 minutes before sleep to these areas allows the nanoemulsion to penetrate into subcutaneous tissue and reach local C-fiber nerve endings, providing localized TRPV1 desensitization at the sites of worst bedding-contact allodynia. The topical route contributes to local pain reduction without adding to total systemic CBD dose — relevant for fibromyalgia patients managing their systemic dose conservatively due to CYP medication interactions. The cream does not contribute to central sensitization mechanism reversal (that requires systemic CBD reaching the CNS) but reduces the peripheral afferent input that is sustaining and triggering central sensitization episodes. Use in combination with oral CBD (not as a substitute) for the most comprehensive coverage: oral for the central alpha-delta anomaly, HPA, and endocannabinoid deficiency mechanisms; topical for the peripheral allodynic tender point mechanism.

Frequently Asked Questions About CBD Oil for Sleep and Fibromyalgia

Related Articles

• → CBD Oil for Sleep and ME/CFS: Alpha-Delta Anomaly, HPA Hypo-Responsiveness, and Post-Exertional Malaise
• → CBD Oil for Sleep and Autoimmune Disease: CB2 Immunomodulation and Cytokine-Driven Sleep Disruption
• → CBD Oil for Sleep and Restless Legs Syndrome: Dopaminergic Pathways, Adenosine-A2A, and Iron Deficiency
• → CBD Oil for Deep Sleep: N3 Slow-Wave Sleep, Glymphatic Clearance, and Restorative Sleep Architecture
• → CBD Oil for Sleep and Diabetes: Glycemic Dysregulation, Nocturnal Hypoglycemia, and DPN Sleep Disruption

References

1. Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
2. Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
3. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
4. Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
5. Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
6. Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352